Abstract

BackgroundAdvances in the treatment of Ewing sarcoma family of tumors (ESFT) are the result of improvements in systemic and local therapies. The individual contributions of each treatment component cannot be analyzed separately; improvements in local and systemic control can influence each other. Patients and methodsWe reviewed the records of 220 patients treated on institutional protocols from 1979 to 2004. Factors predictive of local and distant recurrence were analyzed. ResultsThe median age at diagnosis was 13.7 years. Ninety-five patients relapsed at a median of 1.6 years. The 5-year overall survival estimate was 63.5%±3.5%. The estimated 5-year cumulative incidence (CI) of local failure was 25.1%±3.0%. Local failure was associated with treatment era (P<0.001), tumor size (P=0.037) and type of local control (P=0.021). Systemic treatment intensification improved local control. The estimated 5-year CI of distant recurrence was 22.5%±2.9%. Patients with localized disease (P<0.001), smaller tumors (P=0.018) and those who received surgery±radiation for local control (P=0.023) had lower CI of distant failure. ConclusionsSuccessful treatment of ESFT requires optimal systemic and local therapy. Both treatment modalities are intertwined and the control of both local and distant disease is the result of the combined approach.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.